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Adjuvant antioestrogen therapy with tamoxifen is recommended for all women following breast-conserving surgery for ductal
carcinoma in situ (DCIS) to reduce local recurrence, despite 50% of lesions being oestrogen receptor (OR) negative. We have
investigated the response to hormone manipulation in DCIS by studying changes in epithelial proliferation and progesterone receptor
(PR) expression as surrogate molecular markers of treatment effects in DCIS of known OR status. Women were identified who had
undergone diagnostic core biopsy followed by surgery for DCIS 14–41 days later. Ki67 (a measure of epithelial cell proliferation) and
PR expression were determined by immunohistochemistry on paired paraffin sections of the core biopsy and operative specimens for
each patient, with OR and HER-2 measured on the operative specimen. Women were divided into three groups according to
whether they had changed hormone therapy (stopped hormone replacement therapy (HRT), group 1), continued taking HRT (group
2) or were not taking HRT (group 3) between core biopsy and surgery. In OR-positive (but not in OR-negative) DCIS after
oestrogen withdrawal (group 1), a fall in the mean cell proliferation (Po0.01) was observed. A fall in PR expression between core
biopsy and surgery was also seen in this group (P¼0.02). No change in either mean cell proliferation or PR expression was seen in
the other two groups in OR-positive or -negative DCIS. The fall in proliferation and PR expression occurred regardless of HER-2
status. In conclusion, a biological response to hormone manipulation is only seen in OR-positive DCIS tumours. Any clinical value of
antioestrogen therapy is likely to be restricted to this group.
British Journal of Cancer (2003) 89, 277–283. doi:10.1038/sj.bjc.6601013 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: DCIS; HRT; response; tamoxifen; recurrence; breast
                                                                                                   
Ductal carcinoma in situ (DCIS) accounts for 15–20% of new
breast cancers and up to 40% of mammographic detected cancers
(Ernster et al, 2000). Most patients with DCIS are now offered
breast-conserving surgery (BCS) (Bordeleau et al, 2001) in marked
contrast to the practice two decades ago when mastectomy was the
standard treatment. Breast-conserving surgery, even with the
addition of adjuvant radiotherapy, is associated with local
recurrence (LR) rates of up to 10% at 4 years (Fisher ER et al,
1999; George et al, 2000; Julien et al, 2000) compared to 1–2% after
mastectomy, with about half of all recurrences being invasive
cancers (Solin et al, 2001).
Breast epithelial proliferation is increased by the use of the oral
contraceptive pill (Williams et al, 1991) and hormone replacement
therapy (HRT) use exceeding 5 years duration (Hofseth et al,
1999), although the role of HRT as a risk factor for the
development of DCIS is unclear.
Two studies (Schairer et al, 1994; Longnecker et al, 1996) have
reported a 1.4 increased relative risk (RR) of DCIS development
with use of oestrogen-only HRT preparations and 1.7–2.3 with
combined oestrogen and progesterone therapy. However, other
studies have not shown any increased RR of DCIS, regardless of the
type of HRT preparation used or duration of therapy (Stanford
et al, 1995; Henrich et al, 1998; Gapstur et al, 1999). There are no
data on the risk of HRT use following treatment for DCIS.
The cellular pathogenesis of DCIS is unclear, but the increased
cell proliferation of oestrogen receptor (OR) expressing normal
breast epithelial cells near menopause (Shoker et al, 1999) may
induce low-grade OR-positive DCIS development. No cell pre-
cursor of OR-negative DCIS has been identified, but potentially it
arises from OR-negative luminal epithelial cells.
In the normal breast, epithelial cell coexpression of OR and Ki67
nuclear antigen (a reliable marker of proliferation in breast cancer
(Gonzalez-Vela et al, 2001)) is rare, that is, the OR expressing
normal breast cell population (10%) are nonproliferating. How-
ever, in intraepithelial neoplasia, coexpression is significantly
increased, and correlates positively with the risk of invasive cancer
development (Shoker et al, 1999). The proliferation rate in
OR-negative DCIS has been shown to be greater than in
OR-positive DCIS, and is thought to be due to a transition to
autonomous growth, utilising nonhormonal growth pathways
(Schmitt, 1995).
Antioestrogen therapy with tamoxifen (NSABP P-1 trial, Fisher
et al, 1998) and raloxifene (MORE trial, Cummings et al, 1999) has
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ybeen shown to reduce the development of OR-positive, but not
OR-negative, invasive breast cancer (IBC). Tamoxifen is a selective
OR modulator that blocks the binding of oestrogen to its nuclear
receptor, is cytostatic in action (O’Regan and Jordan, 2002) and
has been shown to reduce cell proliferation in IBC (Clarke et al,
1993) and in normal breast epithelium (Bernardes et al, 1999) as
determined, using Ki67 nuclear antigen immunohistochemistry.
However, tamoxifen induces progesterone receptor (PR) expres-
sion for up to 6 weeks after commencing therapy(Clarke et al,
1993; Chang et al, 2000; Robertson et al, 2001).
Two large randomised clinical trials of adjuvant tamoxifen after
BCS for DCIS have been completed (Fisher B et al, 1999; George
et al, 2000). In the NSABP B-24 trial (Fisher B et al, 1999), women
undergoing tamoxifen therapy for DCIS after radiotherapy (30% of
women were o50 years of age) had a significant reduction in the
number of cancer events compared to placebo in women under-
going surgery and HRT (8.2 vs 13.4%) at 5 years, but this was
largely due to the 40% reduction in recurrence in women under 50
years of age on tamoxifen, whereas only a 20% reduction was seen
in women 450 years of age randomised to tamoxifen. Recent data
from a retrospective pathological review of 628 DCIS tumours out
of the original 1804 in this trial showed 77% OR positivity; a clear
effect of tamoxifen therapy compared to placebo was seen in these
tumours, with a reduction in both ipsilateral and contralateral
local recurrence (Allred et al, 2002). In contrast, no significant
benefit of tamoxifen therapy was seen for OR-negative tumours.
The UK DCIS trial (George et al, 2000), in which 97% of patients
were X50 years of age, found a nonsignificant 20% reduction in
risk of DCIS recurrence from the use of tamoxifen as adjuvant
therapy in this older population. A pathological review of this trial
data is not yet available.
We have shown previously that approximately 50% of high-
grade comedo DCIS is OR negative (Holland et al, 1997) and in a
human DCIS xenograft animal model hormone independent
(Gandhi et al, 2000). These observations together with the data
on the chemoprevention of OR-positive (but not OR-negative) IBC
with antioestrogen therapy (Fisher et al, 1998; Cummings et al,
1999), suggest that there will be no clinical benefit of antioestrogen
therapy after treatment for OR-negative DCIS.
Studies of patients with IBC have shown that early changes (o3
weeks) in cell proliferative indices and PR expression occur after
antioestrogen therapy (Clarke et al, 1993; Chang et al, 2000;
Dowsett et al, 2001a; Robertson et al, 2001; Harper-Wynne et al,
2002) in OR-positive (but not OR-negative) tumours and these
changes are accepted as surrogate markers of clinical tumour
response, with tamoxifen treatment increasing (Chang et al, 2000;
Robertson et al, 2001) and aromatase inhibitor therapy decreasing
PR expression (Miller et al, 2001).
No equivalent studies of hormonal manipulation of DCIS have
been reported. We have utilised the widespread use of core biopsy
to diagnose DCIS, and compared proliferation rates in the paired
core biopsy and operative surgical specimen in women stopping
HRT with a control group who either continued HRT or were not
taking HRT.
The aim of this study was to investigate the effect of hormone
manipulation on epithelial cell proliferation and PR expression in
DCIS in relation to OR status of the DCIS tumours, to evaluate
whether any likely benefit of giving adjuvant tamoxifen therapy or
discontinuing HRT therapy relates to the OR status of the DCIS
tumour.
MATERIALS AND METHODS
Between 1998 and 2000, 108 women had a preoperative breast core
biopsy diagnosis of DCIS (using a 14-gauge needle), followed by
definitive surgery between 14 and 41 days later (median 17 days) at
the University Hospital of South Manchester or the Christie
Hospital, UK. Of these, 52 women were using HRT at the time of
diagnosis and 56 women were not using HRT during the same time
period. These patients form the retrospective study population and
were divided into three groups according to HRT use: Group 1
(n¼27) contained patients who stopped using HRT at core
diagnosis; Group 2 consisted of women who continued to take
HRT between the core biopsy and surgery (n¼25); and Group 3
were not using HRT (or any other hormonal therapy) between
diagnosis and surgery (n¼56), and were designated as a control
group.
The HRT preparations taken by patients in Groups 1 and 2 were
administered orally in 72% and transdermally (patches) in 28%,
and contained oestrogen only in 41% and combined oestrogen and
progesterone in 59%.
Immunohistochemical assay of Ki67, OR, PR and HER-2
Paired paraffin wax sections (3–5mm thick) of tissue from each
patient were mounted on 3-aminopropyltriethoxysilane (APES,
Sigma, Dorset, UK) coated slides, dewaxed in xylene and
rehydrated prior to immunohistochemical staining for Ki67
nuclear antigen labelling (a measure of cellular proliferation),
OR, PR and HER-2. Ki67 was detected using the MIB-1 monoclonal
antibody. Well-established immunohistochemistry protocols de-
veloped at the clinical research laboratory, Paterson Institute for
Cancer Research, Manchester (a UK reference laboratory for HER-
2 immunohistochemical staining) were followed for each marker,
all of which have previously been validated by us and found to be
reproducible in DCIS (Holland et al, 1997; Gandhi et al, 2000;
Dowsett et al, 2001a; Chan et al, 2002). For all markers, antigen
retrieval was achieved by the pressure cooking method for 4min in
citrate buffer (pH¼6.0). After cooling (20min), endogenous
peroxide activity was blocked by incubating the slides in
phosphate-buffered saline (PBS) with 0.3% H2O2 for 20min. A
positive and negative control slide was included in each
immunohistochemical assay. For HER-2, this included sections
of known HER-2-positive invasive breast, and sections of DCIS for
OR, PR and Ki67 were used as determined in previous studies of
DCIS in our department.
Ki67 MIB-1 labelling
Nonspecific binding was blocked by using 10% normal goat
serum and 0.5% casein in PBS with for 30min. Sections were
then incubated with the mouse monoclonal antibody MIB-1 (Dako
Ltd, Cambridge, UK M7240) at a concentration of 1:50 for 1h,
then rinsed in PBS for 10min, followed by incubation with a
biotinylated goat anti-mouse secondary antibody (Dako, E432)
diluted 1:200 for 40min.
OR labelling
Nonspecific binding was blocked by using 10% normal goat serum
and 0.5% casein in PBS with for 30min. Sections were incubated
with mouse anti-human OR (Dako Ltd, UK M7047), at a
concentration of 1:33 for 1h, followed by incubation with a
biotinylated secondary goat anti-mouse antibody (Dako, E432), at
a concentration of 1:200 for 40min.
PR labelling
Nonspecific binding was blocked by using 10% normal rabbit
serum and 0.5%. casein in PBS with for 30min. Sections were
incubated with a mouse anti-human PR (Dako Ltd, UK M3569), at
a concentration of 1:50 for 1h, followed by incubation with a
biotinylated secondary rabbit anti-mouse antibody (Dako, E413),
at a concentration of 1:200 for 40min.
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Nonspecific binding was blocked by using 10% normal rabbit
serum and 0.5%. casein in PBS with for 30min. Sections were
incubated with a mouse anti-human HER-2 (Dako Ltd, UK A485),
at a concentration of 1:40 for 1h, followed by incubation with a
biotinylated secondary rabbit anti-mouse antibody (Dako, E413),
at a concentration of 1:200 for 40min.
Antigen visualisation
For each antigen, following incubation with the secondary
antibody, the tissue was then rinsed in PBS followed by incubation
with a standard streptavidin–biotin complex (ABC, Vector labs,
Peterborough, UK, PK-6100) for 30min. Staining was then
visualised using diaminobenzidene chromogen (DAB, Dako Ltd,
Cambridge, UK) in 0.1% H2O2 PBS solution and sections
counterstained with Gill’s haematoxylin.
Immunohistochemical scoring
Immunostaining was nuclear for Ki67, OR and PR and predomi-
nantly cell membranous for HER-2 with a cytoplasmic component.
For each section, a minimum of 1000 cells were scored across
randomly selected areas of DCIS at a magnification of  400 using
a grid graticule and cell counter. Ki67, OR and PR scores were
calculated as the percentage of positively DAB-stained nuclei (i.e.
positive cells/total number of cells  100%). Oestrogen receptor
and PR positivities were defined as X5% stained nuclei; consistent
with that used for IBCs. HER-2 staining was scored 0 (absent) to 3
(maximum cytomembranous staining seen, comparable to invasive
cancer control), with a score X2 considered HER-2 positive.
Statistical analysis
Statistical analysis was performed using SPSS software (SPSS,
Chicago, IL, USA). Changes in proliferative indices and receptor
expression levels between core biopsy specimens and operative
specimen for each subgroup were compared using paired sample
t-tests. The magnitude of changes in different parameters across
different patient groups was compared using the Kruskal–Wallis
test. A significance level of 5% was used throughout.
RESULTS
The median age of the patients in the three groups (Group 1:
women stopped HRT; Group 2: patients continued HRT and Group
3: were not using HRT between core biopsy and surgery) was
similar: 56 (range 46–77), 56 (range 42–63) and 57 (range 34–83)
years, respectively (P¼0. 70, Kruskal–Wallis test). High nuclear
grade DCIS (grade 3) was present in 63, 48 and 66% of tumours in
the three groups, respectively (P¼0.57, Kruskal–Wallis). Despite
the lower frequency of high-grade lesions in the HRT continued
group (n¼25), the proportion of OR-positive tumours across the
three groups (67, 76 and 57%, respectively) did not differ (P¼0.27,
w
2 test).
Effects of hormone manipulation on cell proliferation
In no OR-negative DCIS tumours, irrespective of group, was a
change in cell proliferation seen between core biopsied and
operative specimen. In particular, in the hormonally manipulated
group (HRT stopped), the OR-negative DCIS tumours showed no
change in mean cell proliferation between core biopsy and
operation (Table 1).
In the 18 OR-positive DCIS tumours patients who were
hormonally manipulated (HRT stopped), a significant reduction
in cell proliferation between core biopsy and surgery (mean Ki67
LI on core¼9.95%, mean Ki67 % LI at operation¼5.06, Po0.01)
occurred. In OR-positive DCIS from women who continued HRT
or were not taking HRT, no change in the mean DCIS cell
proliferation between core biopsy and surgery was seen (Table 1).
The hormone manipulated OR-positive DCIS (HRT stopped,
n¼18) were further analysed to assess the response in individual
tumours in the group. Despite all DCIS tumours in this subgroup
expressing OR (X5%), only approximately half the tumours
showed a reduction in proliferation during the period of hormone
withdrawal, a finding that was independent of nuclear grade (50%
high-grade DCIS showed a fall in cell proliferation).
An across-group comparison was made of the magnitude of
change in DCIS cell proliferation between core biopsy and surgery
according to OR status (Table 1, Figure 1). In OR-positive DCIS
tumours, the fall in proliferation was much greater in group 1
(HRT withdrawal) compared to the other two groups (P¼0.02).
No difference in the magnitude of change in proliferation across
the groups was seen in the OR-negative DCIS tumours (P¼0.73,
Table 1, Figure 1).
Effect of hormone manipulation on PR expression
Progesterone receptor expression was determined on 99 DCIS
tumours in this series. Of these, 29 were PR negative and 70 PR
positive (stopped using HRT, n¼19; continued to take HRT,
Table 1 Changes in cell proliferation (Ki67) in DCIS between core biopsy and surgery by OR status
OR status Patient group
% High
grade
Mean core
biopsy Ki67
LI (s.e.)
Mean operation
Ki67 LI (s.e.)
95% CI of
the mean
difference P-value
a
Median Ki67 change
core biopsy to
operation (IQR) P-value
b
Negative (n¼39) Stopped HRT (n¼9) 78 16.94 (3.01) 16.07 (2.13)  2.09 to 3.83 0.52  0.45 ( 1.76 to +1.84)
Continued HRT (n¼6) 33 10.84 (4.57) 12.72 (4.62)  6.19 to 2.45 0.32 +0.42 ( 0.25 to +3.44) 0.77
Not using HRT (n¼24) 67 12.52 (1.62) 11.99 (1.55)  1.59 to 2.66 0.61 +0.19 ( 4.15 to +3.09)
Positive (n¼69) Stopped HRT (n¼18) 56 9.95 (1.89) 5.06 (1.39) 2.07 to 7.71 o0.01  3.02 ( 7.68 to  0.84)
Continued HRT (n¼19) 53 10.27 (1.79) 9.79 (1.72)  2.64 to 3.60 0.75  0.60 ( 2.94 to +4.47) 0.02
Not using HRT (n¼32) 65 10.81 (1.34) 10.31 (1.76)  2.60 to 3.61 0.74  0.52 ( 2.4 to +0.34)
aPaired samples t-test for change in Ki67 between core biopsy and surgery for each subgroup.
bKruskal–Wallis test for the magnitude of change in Ki67 across groups.
DCIS¼ductal carcinoma in situ;O R¼oestrogen receptor; LI¼labelling index (% of nuclei labelled); CI¼confidence interval; s.e.¼standard error of mean; IQR¼interquartile
range. Changes in DCIS cell proliferation (Ki67 labelling index) between core biopsy and surgery (14–41 days later), with women placed in three groups: stopped HRT,
continued HRT and not using HRT. For each group, the DCIS tumours are divided into OR positive and OR negative. The mean Ki67 LI score (%) is given for each subgroup at
core biopsy and operation along with the standard error of the mean for each, and differences in the means for the paired samples are compared using a t-test. Oestrogen
receptor-positive DCIS in the HRT stopped subgroup showed a fall in cell proliferation between core biopsy and operation. The median change in Ki67 (with an interquartile
range) for each patient group by OR status is shown. No change was seen in OR-negative tumours across groups (P¼0.77), whereas OR-positive DCIS from women stopping
HRT showed larger changes in proliferation compared to OR-positive tumours in the other groups (P¼0.02).
)
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yn¼19; and not using HRT, n¼32). A significant fall in cell
proliferation was observed in women with PR-positive DCIS
stopping HRT between core biopsy (mean 11.1, s.e. 1.62) and
surgery (mean 6.8, s.e. 1.52, Po0.01), but in no other group.
However, paired core biopsy/operation expression data were only
available for 40 of these because of insufficient core tissue
remaining after Ki67 analysis.
Out of the 40 PR-positive tumours with paired data, 14 patients
stopped HRT. In these, a significant fall in the mean PR expression
was observed between core biopsy (mean, 42.3%) and operation
(mean 29.2%, P¼0.009). No difference in the mean PR expression
between core biopsy and surgery was seen in women who
continued HRT (n¼11) or were not taking HRT (n¼15, Table 2).
An across-group comparison of the magnitude of change in PR
expression between core biopsy and operation groups (Table 2)
showed a significant difference between the groups due to the
effect of the PR reduction in the HRT-stopped group (P¼0.002,
Kruskal–Wallis). In women who were not using HRT, a
nonsignificant increase in PR expression was seen.
Comparing PR and Ki67 change in those patients stopping HRT,
the magnitude of reduction in PR expression (median  15.00%)
was greater than the magnitude of reduction in Ki67 (median
 3.01%, Po0.01, Wilcoxon signed-rank test).
HER-2 expression
This was determined on 92 operative tissue samples. The overall
HER-2 positivity was 66%. HER-2 expression was significantly
greater in OR- or PR-negative than OR- or PR-positive DCIS
(HER-2 positive tumours, 48% OR positive and 58% PR positive;
HER-2 negative tumours, 87% OR positive and 93% PR positive
(Po0.001, Mann–Whitney U-test). There was no difference in the
median HER-2 expression between tumours in the three patient
groups (P¼0.26, Kruskal–Wallis).
HER-2 expression did not affect response to oestrogen with-
drawal (P¼0.27, Mann–Whitney U-test). Specifically, the reduc-
tion response in Ki67 cell proliferation between core biopsy and
surgery in OR-positive DCIS was seen equally in both HER-2-
positive and -negative DCIS (P¼0.02 and 0.03, respectively, paired
samples t-test).
DISCUSSION
The time period between diagnostic core biopsy and operation
represents an important window to investigate the effects of drug
therapy.
In IBC, OR status predicts response to preoperative therapy in
OR-positive cancers treated with tamoxifen (Clarke et al, 1993;
Chang et al, 2000), arimidex (Miller et al, 2001; Geisler et al, 2001),
letrozole (Ellis et al, 2001) and faslodex (Robertson et al, 2001). In
addition, OR status predicts adjuvant response to tamoxifen and is
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Figure 1 Comparison of the changes in cell proliferation (Ki67) between
core biopsy and surgery in the DCIS tumours across groups (stopped HRT,
continued HRT and not using HRT) by OR status. For each group, median
values are shown as thick horizontal lines, the boxes represent interquartile
range and the bars the full range. In OR-positive DCIS tumours (A), the
median change in proliferation in the stopped HRT is significantly greater
than other groups (P¼0.02, Kruskal–Wallis). There was no difference in
the changes in proliferation across groups in OR-negative tumours (B),
P¼0.77.
Table 2 Change in PR expression in DCIS between core biopsy and operation
Patient group (n)
Mean core
PR LI (s.e.)
Mean op
PR LI (s.e.)
95% CI of PR
LI difference P-value
a
Median change in
PR LI (IQR) P-value
b
Stopped HRT (14) 46.2 (9.4) 29.2 (7.9) 4.9 to 29.0 0.009  10.0 ( 31.3 to  1.00) 0.002
Continued HRT (11) 55.9 (11.9) 56.5 (12.2)  4.9 to 3.7 0.75 0.0 ( 1.0 to 6.0)
Not using HRT (15) 42.3 (8.7) 51.5 (8.9)  19.6 to 1.2 0.08 +5.0 ( 4.2 to 16.0)
aPaired samples t-test for change in PR expression between core biopsy and surgery for each subgroup.
bKruskal–Wallis test for the magnitude of change in PR across groups.
LI¼Labelling Index (% of nuclei labelled); CI¼confidence interval; s.e.¼standard error of mean; IQR¼interquartile range. Progesterone receptor-expression data for 40 PR-
positive DCIS tumours for which paired sample data between core biopsy and operation (14–41 days later) were available. Women stopping HRT show a significant fall in DCIS
PR expression (P¼0.009). A mean PR increase in women not using HRT was seen between core biopsy and surgery (P¼0.08). The magnitude of change in PR expression
across the groups was also significant (P¼0.002).
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reduction in death from IBC of 23% for OR-rich tumours but with
no benefit for OR-poor tumours (Early Breast Cancer Trialists’
Collaborative Group, 1998).
In OR-positive IBC, changes in cellular proliferation measured
by Ki67 nuclear antigen labelling can be used to reliably predict the
response to antioestrogen therapy (Clarke et al, 1993; Chang et al,
2000; Dowsett et al, 2001a; Robertson et al, 2001; Harper-Wynne
et al, 2002).
No studies have addressed the biological effect of hormone
manipulation on DCIS. In particular, we know of no studies that
have examined the effect of a change in HRT on cell proliferation
in breast cancer (in situ or invasive). However, most clinicians
recommend stopping HRT on diagnosis of DCIS, despite the lack
of evidence for any biological benefit.
In this study, we have used changes in DCIS cell proliferation
and progesterone receptor expression as surrogate markers of
likelihood of tumour response to hormonal manipulation to
evaluate the potential benefit of stopping HRT in preventing local
recurrence after BCS for DCIS based on the OR status of the DCIS
tumours.
This was a retrospective, nonrandomised study of consecutive
women presenting with DCIS in one unit, and is limited because of
small numbers when patients are divided into subgroups.
However, we have clearly demonstrated a significant fall in the
proliferation in DCIS epithelium following a period of oestrogen
withdrawal in OR-positive (but not in OR-negative) tumours,
consistent with that reported in OR-positive IBC after treatment
with either aromatase inhibitors (Ellis et al, 2001; Miller et al,
2001) or tamoxifen (Chang et al, 2000). Furthermore,
PR-expressing DCIS also showed a fall in the level of PR expression
(an oestrogen-dependent protein) when HRT was withdrawn. No
changes in cell proliferation in DCIS tumours were seen in patients
not taking HRT or those continuing HRT during the period
between core biopsy and surgery, irrespective of OR status; these
patient groups represented internal controls.
The observation that oestrogen withdrawal does not result in a
change in cell proliferation in OR-negative DCIS supports our
previous findings in a human xenograft mouse model of DCIS
demonstrating the hormone independence of OR-negative DCIS
(Holland et al, 1997). The growth of OR-negative DCIS is driven by
activation of the type-1 tyrosine kinase cell surface receptors
epidermal growth factor receptor (EGFR) and HER-2 receptor and
can be inhibited by EGFR receptor antagonists (Chan et al, 2002).
This study provides further evidence in patients that OR-negative
DCIS is oestrogen independent.
Using the DCIS animal model, we have also shown that
apoptosis (programmed cell death, another index of cell turnover)
increases in OR-positive, but not OR-negative, DCIS following
antioestrogen therapy with the pure antioestrogen, faslodex.
However, these apoptotic changes occur earlier than 14 days
following treatment, and a recent clinical trial investigating the
short-term biological effects of antioestrogen therapy in IBC did
not demonstrate any change in apoptosis in the period upto 21
days after treatment with either faslodex or tamoxifen (Robertson
et al, 2001). Therefore, we did not use apoptosis to assess tumour
response to a change in therapy during the 14–41 day period used
in this study (Leal et al, 1995).
The retrospective analysis of OR status in approximately one-
third of DCIS tumours from the NSABP B-24 trial (by case note
review and central Immunohistochemical assay) has been con-
firmed in the findings of this study in the clinical setting, with
DCIS OR positivity associated with a significant reduction in the
risk of LR after tamoxifen therapy (RR¼0.41, confidence interval
(CI)¼0.25–0.65, P¼0.0002), while OR-negative tumours showed
a nonsignificant benefit in reducing LR from therapy (RR¼0.8, CI
0.41–1.56, P¼0.51). However, the total number of events in the
latter group was deemed too small to exclude a small benefit
(Allred et al, 2002). Since the B-24 trial contained many women
with DCIS at the excision margins, these results do not
demonstrate the actual benefit of tamoxifen by OR status in
reducing LR when DCIS has been completely excised.
The authors of the NSABP B-24 trial (Fisher B et al, 1999)
recommend tamoxifen (in combination with radiotherapy) for all
patients following BCS for DCIS despite the side effects of
vasomotor symptoms and potential increased risk of thromboem-
bolic disease and endometrial cancer induced by tamoxifen (Fisher
et al, 1998). We believe that this recommendation is not
biologically (present study) or clinically (pathological review
findings of the B-24 trial (Allred et al, 2002)) justifiable and needs
revision.
HER-2 (CerbB-2/Neu) expression in IBC is associated with
hormone unresponsiveness, even when OR is expressed (Dowsett
et al, 2001b). We found no evidence in this study that HER-2
expression in DCIS adversely affects the biological response to
oestrogen withdrawal, although HRT (oestrogen) withdrawal is
more closely related in nature to aromatase inhibition than to
tamoxifen therapy. There have been no trials of adjuvant
aromatase inhibition after the treatment for DCIS. This is an area
that needs to be addressed, since HER-2 receptor is overexpressed
in approximately 60% of DCIS (Leal et al, 1995).
Since contralateral breast cancer after treatment for DCIS occurs
at a rate of approximately 1% per year for 10 years and since
prophylactic tamoxifen therapy in women at high risk for breast
cancer reduces DCIS occurrence by 50% and reduces OR-positive
(but not OR-negative) IBC occurrence by 69% (Fisher et al, 1998),
its role as a chemopreventative agent could be used to justify its
use in women with OR-negative DCIS to prevent a small number of
de novo OR-positive cancer occurrences in these high-risk women.
However, a recent meta-analysis of the results of adjuvant
tamoxifen therapy trials for early IBC found no conclusive data
on either survival benefit or reduction in contralateral breast
cancer recurrence to support the use of tamoxifen for women with
OR-negative breast cancer (Fisher B et al, 1998, 1999).
Only approximately 50% of cases of DCIS are OR positive
(Chaudhuri et al, 1993). We have shown in this study that only
approximately 50% of the OR-positive DCIS respond to oestrogen
withdrawal, suggesting that as few as 25% of patients with DCIS
may benefit from hormonal manipulation as an adjuvant
treatment. The present study was designed to demonstrate the
biological response of DCIS to short-term hormone manipulation,
not to assess LR risk in this patient cohort; this can only be
assessed prospectively in trials using hormone therapy (antioes-
trogen or hormone replacement) in women where the OR status of
the tumours is known.
It is likely that the side-effect profile of long-term tamoxifen use
(including pulmonary embolism, deep vein thrombosis and
endometrial cancer) will outweigh any clinical benefit for
OR-negative DCIS or, indeed, if given to unselected women with
DCIS. The UK committee on safety of medicines and the medicines
control agency (March 2002) have recommended that tamoxifen
should no longer be used for the chemoprevention of breast cancer
mainly because of the associated thromboembolic risk (Committee
on Safety of Medicines and the Medicines Control Agency, 2002).
Adjuvant hormonal treatment of women with DCIS now needs
to be individualised, a goal that has been achieved for IBC and one
that we should now aim for in DCIS. For patients with OR-positive
DCIS, clinicians should endeavour to enrol as many patients as
possible into clinical trials to compare the efficacy of aromatase
inhibitors with tamoxifen to profile new relative clinical benefits
(e.g. the International Breast Cancer DCIS study II).
This study highlights the biological importance of OR status in
predicting response to hormonal therapy for DCIS. At present, the
use of HRT after treatment for DCIS should be restricted to women
with OR-negative tumours, since these are biologically unrespon-
sive to oestrogen, and therefore HRT therapy should not affect the
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yrisk of local recurrence. Oestrogen receptor-negative DCIS has
been shown to be hormone independent, thus adjuvant tamoxifen
therapy in women with OR-negative DCIS is likely to produce
increased morbidity without any clinical benefit. Oestrogen
receptor status should now be determined prospectively on all
newly diagnosed DCIS and should be used to guide the use of
adjuvant hormone therapy.
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